← FDA ENFORCEMENT
D-0040-2027Class II
Houston Rx LLC
What this record is not
A recall record is reproduced as FDA published it, and the classification is FDA’s. SPEQ adds no interpretation, and a recall concerns the products and dates in the record — it is not a statement about a company’s other products or its current status.
Recalling firm
Houston Rx LLC
Product type
Drug
Status
Ongoing
Report date
2026-10-21
Distribution
Nationwide in the USA.
Firm state
TX
Product quantity
64 vials
Initiated by
Voluntary: Firm initiated
SPEQ quality domain
Environmental MonitoringReason for recall
Lack of assurance of sterility.
Product description
Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Code / lot info
Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.
Data: U.S. FDA. Recall details are as reported by the FDA. The quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Open the enforcement explorer →